People with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists have a lower risk for serious renal adverse events than those given dipeptidyl peptidase-4 inhibitors, indicate results from a Scandinavian real-world study.
A post-hoc analysis of the LEADER trial suggests that liraglutide reduces cardiovascular risk in people with type 2 diabetes regardless of whether they have heart failure.
The failure of intensive medication to halt beta-cell decline in children with early type 2 diabetes occurs despite them having better baseline beta-cell and alpha-cell function than newly diagnosed adults, say the RISE researchers.
Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.
With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.